Shares of bluebird bio Inc (NASDAQ:BLUE) have earned a consensus rating of “Buy” from the eighteen analysts that are currently covering the firm. One analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and ten have issued a buy recommendation on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $88.68.

BLUE has been the subject of several research reports. Jefferies Group LLC reissued a “buy” rating and set a $88.00 price objective on shares of bluebird bio in a research note on Friday, March 24th. Zacks Investment Research lowered shares of bluebird bio from a “hold” rating to a “sell” rating in a report on Tuesday, April 25th. Roth Capital restated a “neutral” rating and set a $71.00 target price (down previously from $87.00) on shares of bluebird bio in a report on Monday, February 6th. Maxim Group set a $87.00 price objective on shares of bluebird bio and gave the stock a “buy” rating in a report on Friday, February 3rd. Finally, BTIG Research reiterated a “buy” rating on shares of bluebird bio in a report on Monday, May 1st.

bluebird bio (NASDAQ:BLUE) traded down 4.92% during mid-day trading on Tuesday, reaching $84.10. 479,060 shares of the company’s stock were exchanged. bluebird bio has a one year low of $35.75 and a one year high of $100.40. The stock has a 50-day moving average of $87.51 and a 200-day moving average of $75.49. The stock’s market cap is $3.44 billion.

bluebird bio (NASDAQ:BLUE) last announced its quarterly earnings data on Wednesday, May 3rd. The biotechnology company reported ($1.68) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.76) by $0.08. bluebird bio had a negative net margin of 3,941.72% and a negative return on equity of 30.79%. The company had revenue of $6.83 million during the quarter, compared to analysts’ expectations of $1.51 million. On average, equities research analysts anticipate that bluebird bio will post ($6.94) earnings per share for the current year.

In related news, Director John Maraganore sold 13,839 shares of the business’s stock in a transaction dated Friday, March 3rd. The shares were sold at an average price of $85.02, for a total transaction of $1,176,591.78. Following the completion of the sale, the director now owns 5,765 shares of the company’s stock, valued at approximately $490,140.30. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Daniel Lynch sold 1,000 shares of the business’s stock in a transaction dated Thursday, April 27th. The shares were sold at an average price of $90.01, for a total transaction of $90,010.00. Following the sale, the director now directly owns 2,400 shares of the company’s stock, valued at approximately $216,024. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 29,256 shares of company stock valued at $2,603,418. Insiders own 3.50% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Martingale Asset Management L P boosted its position in bluebird bio by 0.6% in the first quarter. Martingale Asset Management L P now owns 17,008 shares of the biotechnology company’s stock valued at $1,547,000 after buying an additional 100 shares during the period. Legal & General Group Plc boosted its position in bluebird bio by 2.6% in the first quarter. Legal & General Group Plc now owns 13,944 shares of the biotechnology company’s stock valued at $1,272,000 after buying an additional 357 shares during the period. First Mercantile Trust Co. boosted its position in bluebird bio by 14.4% in the first quarter. First Mercantile Trust Co. now owns 2,897 shares of the biotechnology company’s stock valued at $263,000 after buying an additional 365 shares during the period. Dimensional Fund Advisors LP boosted its position in bluebird bio by 0.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 68,220 shares of the biotechnology company’s stock valued at $4,210,000 after buying an additional 540 shares during the period. Finally, California State Teachers Retirement System boosted its position in bluebird bio by 1.0% in the third quarter. California State Teachers Retirement System now owns 78,487 shares of the biotechnology company’s stock valued at $5,320,000 after buying an additional 800 shares during the period.

WARNING: “bluebird bio Inc (BLUE) Given Consensus Recommendation of “Buy” by Analysts” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/05/19/bluebird-bio-inc-blue-given-consensus-recommendation-of-buy-by-brokerages-updated.html.

bluebird bio Company Profile

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

5 Day Chart for NASDAQ:BLUE

Receive News & Stock Ratings for bluebird bio Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc and related stocks with our FREE daily email newsletter.